Market Closed -
Bombay S.E.
06:00:50 2024-05-03 am EDT
5-day change
1st Jan Change
1,655
INR
+0.46%
+2.44%
+25.11%
Sales 2024 *
199B
2.38B
Sales 2025 *
217B
2.61B
Capitalization
754B
9.04B
Net income 2024 *
19.85B
238M
Net income 2025 *
23.23B
278M
EV / Sales 2024 *
3.92
x
Net Debt
2024
*
24.9B
298M
Net Debt
2025
*
9.52B
114M
EV / Sales 2025 *
3.51
x P/E ratio 2024 *
38.3
x
P/E ratio 2025 *
32.7
x
Employees
20,933
Yield 2024 *
0.43%
Yield 2025 *
0.52%
Free-Float
52.83%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Lupin Receives US FDA Inspection Report for Aurangabad, India Manufacturing Facility
Apr. 23
MT
INDIA STOCKS-Indian shares rise tracking Asia rebound; drop in HDFC Bank caps gains
Apr. 22
RE
Lupin Launches Mirabegron Extended-Release Tablets in US
Apr. 21
MT
Lupin Limited Announces Launch of Mirabegron Extended-Release Tablets, 25 Mg, in the United States, After Having Received an Approval from the United States Food and Drug Administration
Apr. 20
CI
US FDA Clears Lupin's API Plant in Gujarat, India, Following GMP Inspection
Apr. 12
MT
Lupin Launches Generic Version of Oracea (Doxycycline Capsules) in US
Apr. 09
MT
Lupin Launches Generic Drug for Inflammatory Lesions of Rosacea in US
Apr. 09
MT
Lupin Limited Announces the Launch of First Generic Version of Oracea® (Doxycycline Capsules, 40 Mg), in the United States
Apr. 09
CI
Indian Equities Close with Marginal Loss on Wednesday as Traders Scale Down Hopes on US Rate Cuts
Apr. 03
MT
Lupin Names Chief Quality Officer
Apr. 03
MT
Lupin Limited Announces Change in Management
Apr. 03
CI
Lupin to Transfer Trade Generics Business to Subsidiary Lupin Life Sciences
Mar. 25
MT
Lupin Limited Receives an Order from the Additional Commissioner of State Tax, Central Division, Patna
Mar. 21
CI
Indian Equities Start Week in Black, Aided by Major Auto and Metal Firms
Mar. 18
MT
Lupin Names Chief Technical Operations Officer
Mar. 18
MT
More news
EXCLUSIVA-Eli Lilly podría lanzar un fármaco contra la obesidad en India el próximo año: presidente ejecutivo
Feb. 28
Wall Street fait relâche
Jan. 15
En Direct des Marchés : ArcelorMittal, Airbus, Atos, Casino, Deutsche Bank, SoftwareOne, Baidu...
Jan. 15
EN DIRECTO DESDE LOS MERCADOS: ArcelorMittal, Airbus, Apple, FedEx, EQT, Citigroup, Deutsche Bank, SoftwareOne, Baidu...
Jan. 15
Accenture : accompagne la transformation de Lupin Limited
22-06-20
More news 1 day +0.46%
1 week +2.44%
Current month +0.60%
1 month +3.16%
3 months +10.14%
6 months +39.62%
Current year +25.11%
More quotes
Managers
Title Age Since
Chief Executive Officer
56
96-12-31
President
-
-
Director of Finance/CFO
59
07-08-12
Members of the board
Title Age Since
Director/Board Member
74
15-10-26
Director/Board Member
69
21-01-27
Director/Board Member
50
95-12-31
More insiders
Date
Price
Change
Volume
24-05-03
1,655
+0.46%
41,878
24-05-02
1,648
+0.14%
8,418
24-04-30
1,645
+0.48%
54,144
24-04-29
1,638
+1.34%
32,803
24-04-26
1,616
+1.31%
42,605
Delayed Quote
Bombay S.E., May 03, 2024 at 06:00 am EDT
More quotes
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas:
- design and production of generic and brand-name formulations;
- production of active pharmaceutical ingredients.
At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil.
Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
More about the company
Last Close Price
1,655
INR
Average target price
1,516
INR
Spread / Average Target
-8.41%
Consensus
1st Jan change
Capi.
+25.11% 9.05B +26.08% 662B +21.85% 546B -4.77% 359B +16.97% 323B +5.69% 290B +13.68% 234B +3.65% 198B -11.12% 194B -3.40% 157B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1